Osimertinib plus Ramucirumab: The Best of Both Worlds?

Clin Cancer Res. 2021 Feb 15;27(4):905-907. doi: 10.1158/1078-0432.CCR-20-4026. Epub 2020 Dec 17.

Abstract

Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.See related article by Yu et al., p. 992.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use
  • Ramucirumab

Substances

  • Acrylamides
  • Aniline Compounds
  • Antibodies, Monoclonal, Humanized
  • Protein Kinase Inhibitors
  • osimertinib
  • ErbB Receptors